Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study
- 25 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (4) , 697-705
Abstract
Background: Growing evidence has shown that cholesterol metabolism abnormalities involve carcinogenesis. Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors have been reported to inhibit tumour progression and prevent ultraviolet-related skin damage. Objectives: To investigate the association of PCSK9 inhibitors with the risk of nonmelanoma skin cancer (NMSC). Methods: This retrospective cohort study analysed data from the US Collaborative Network in the TriNetX database. Adults aged ≥ 40 years with atherosclerotic cardiovascular disease (ASCVD) under statin therapy between 2016 and 2022 were identified. A target trial design was used to compare the risk of NMSC, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), in patients also treated with PCSK9 inhibitors or continuing statin treatment (the control group). Each head-to-head comparison involved propensity score matching. Hazard ratios (HRs) were estimated using Cox proportional hazard models. Stratified analyses based on age, sex, Fitzpatrick skin type and immune status were also performed. Results: A total of 73 636 patients with ASCVD were analysed. Compared with the control group, patients with ASCVD initiating PCSK9 inhibitors had lower risks of developing NMSC [HR 0.78, 95% confidence interval (CI) 0.71–0.87], BCC (HR 0.78, 95% CI 0.69–0.89) and cSCC (HR 0.79, 95% CI 0.67–0.93). Subanalyses revealed a reduced risk of NMSC with each PCSK9 inhibitor, namely evolocumab and alirocumab. Stratified analyses showed similar results in patients aged 65–79 years, those older than 80 years and in men. Conclusions: Our study indicated that patients with ASCVD taking PCSK9 inhibitors have a lower risk of incident NMSC than those not taking PCSK9 inhibitors.Keywords
Funding Information
- Taipei Veterans General Hospital (V111C-044, V111C-029, V112C-111, V112C-140)
- Ministry of Science and Technology (109-2314-B-010-050-MY3, 110-2314-B-075-068)
This publication has 52 references indexed in Scilit:
- A prospective cohort study exploring the joint influence of sunlight exposure and tanning bed use on basal cell carcinoma, squamous cell carcinoma, and melanoma riskArchives of Dermatological Research, 2024
- Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021JAMA Oncology, 2022
- Validity of Using Billing Codes From Electronic Health Records to Estimate Skin Cancer CountsJAMA Dermatology, 2021
- Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibitionBioFactors, 2020
- Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research DatalinkInternational Journal of Cancer, 2017
- Application of Recursive Partitioning to Derive and Validate a Claims-Based Algorithm for Identifying Keratinocyte Carcinoma (Nonmelanoma Skin Cancer)JAMA Dermatology, 2016
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Risk Factors for Single and Multiple Basal Cell CarcinomasArchives of Dermatology, 2010
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Methods for evaluation of medication adherence and persistence using automated databasesPharmacoepidemiology and Drug Safety, 2006